Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Corporation Stock Briefly Spiked Today

By George Budwell - Apr 3, 2017 at 10:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dynavax's Heplisav-B is headed to an advisory committee meeting this July.

What happened

Shares of Dynavax Technologies Corporation (DVAX 4.75%) gained as much as 19% in pre-market trading this morning on the news that the Food and Drug Administration's vaccines and related biological products advisory committee (VRBPAC) will review the company's experimental hepatitis B vaccine, Heplisav-B, on July 28, 2017. Even though this advisory committee meeting will be held less than two weeks ahead of Heplisav's scheduled Prescription Drug User Fee Act (PDUFA) target action date of Aug. 10, 2017, Dynavax said the FDA isn't currently planning on changing this date.

A senior man getting a vaccine from his doctor

Image source: Getty Images.

Despite this surge in pre-market trading, Dynavax's shares opened up only 6% higher, and have steadily cooled off as the market digests this regulatory update. 

So what

An advisory committee meeting tends to be held when the FDA has outstanding questions about an experimental medical product after a formal internal review has been conducted. In this case, the FDA appears dubious about Heplisav's risk-to-reward profile, which is probably going to be the central theme of the advisory committee.

The big picture issue is that GlaxoSmithKline's (GSK -0.64%) Engerix-B and Merck's (MRK 1.24%) Recombivax HB are already on the market for this indication, meaning that there's no overwhelmingly pressing need to approve yet another hepatitis B vaccine. 

Now what

The one issue working in Heplisav's favor is that there is a documented need for vaccines that target specific subpopulations like diabetics. Review studies, after all, have shown that Engerix-B and Recombivax HB tend to produce fairly weak levels of seroprotection in diabetics compared to non-diabetics. However, the FDA doesn't seem to think this gap in care is sufficient to green-light Heplisav without rigorously vetting its potential side effects.  

The bottom line is that an advisory committee is somewhat of a neutral event in Heplisav's case. The FDA's reluctance to approve this vaccine because of rare side effects like Wegener's Granulomatosis isn't exactly a new issue, so an external review was probably always in the cards. At least this time around, investors will get to hear the FDA's side of the story -- instead of having to rely on Dynavax's broad strokes version following a Complete Response Letter. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$17.44 (4.75%) $0.79
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$88.49 (1.24%) $1.08
GSK Stock Quote
$40.31 (-0.64%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.